messaggio
clik on the image and visit the new site
"In silico"
From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".
In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson
Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.
Phage Therapy is influenced by:
Phage therapy is influenced by:
Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail
My point of view
Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail
My point of view
Tuesday, 1 September 2009
Mycobacterium ulcerans project
Some of you are going to consider me a raving mad but, from this date ,I am investigating in depth a possible application of Phage therapy in Mycobacterium ulcerans infections.
The project has a lot of critical points ( for example: Mycobacterium ulcerans goes inside the cells) but for me this is stimulating and I will try to find a solution one by one to all these points .
This work is an example of Phage therapy application to one complex model for anyone that is interested in Phage Therapy.
From:
"Host range of 14 mycobacteriophages in Mycobacterium ulcerans and ..."
At the moment it is the unique scientific work that tackles with light hand a possible application for phage therapy in Mycobacterium ulcerans infections.
Our Knowledge about a potential use of Mycobacteriophages in Phage therapy is still insufficient.
In the Net if we pay attention to information about Mycobacteriophages we can note that all these information are regarding a little number of usual mycobacteriophages: L5, D29 ,BxB1, TM4 and some others.
From NCBI it is possible to find for these phages the genome's map and also for mycobacteriophages of recent discovery from soil by the Phage Hunter program. After nothing else.
My first phage DS6A is still unknown for most of one 's genome.